TLP
KZR

Tri Locum Partners’s Kezar Life Sciences KZR Stock Holding History

Tri Locum Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47,354
Closed -$3.33M – 67
2022
Q4 		$3.33M Sell
47,354
-23,619
-33% -$1.75M 1.35% 27
2022
Q3 		$6.11M Buy
70,973
+20,539
+41% +$2M 1.68% 23
2022
Q2 		$4.17M Sell
50,434
-22,656
-31% -$2M 1.71% 20
2022
Q1 		$12.1M Sell
73,090
-162
-0.2% -$23.3K 4.75% 7
2021
Q4 		$12.2M Buy
+73,252
New +$8.27M 4.82% 7

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Tri Locum Partners's KZR Position: Q1 2023 in Review

Tri Locum Partners sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 47,354 shares — an estimated $3.33M sold.

Tri Locum Partners first reported a position in KZR in Q4 2021 and held it in 5 quarters. The position peaked at $12.2M in Q4 2021. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Tri Locum Partners reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 47,354 Kezar Life Sciences shares in Q1 2023, an estimated $3.33M.
  • Tri Locum Partners first reported a position in Kezar Life Sciences in Q4 2021 and held it in 5 quarters.
  • Tri Locum Partners's Kezar Life Sciences position peaked at $12.2M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.